2021 Revenues ($USD) : $22,449,436,100
2021 Revenues (foreign currencies) : €18,976,700,000
2021 R&D spend : $1,122,903,600
2021 Number of Employees : 3,082
Fiscal Year End : 12/31/2021
Leader : CEO Uğur Şahin

After allying with Pfizer early in the pandemic, mRNA-specialist BioNTech shipped billions of doses of COVID-19 vaccine across the world in 2021. The company brought in nearly €19.0 billion in revenue in 2021. For comparison, BioNTech’s revenues a year earlier were €482.3 million. The cash from its COVID-19 vaccine in 2021 helped it advance its oncology pipeline and launch multiple studies, including Phase 2 studies related to melanoma, head and neck cancers, multiple solid tumors and colorectal cancer. In 2022, the company plans on spending between €1.4 billion to €1.5 billion on R&D. —BB